Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

A Retrospective Analysis From a Single Tertiary Academic Medical Center

Trodello, Cameron, BA*; Higgins, Shauna, MD*; Ahadiat, Omeed, BS*; Ragab, Omar, MD; In, Gino, MD; Hawkins, Makenzie, MSPH§; Wysong, Ashley, MD, MS*

doi: 10.1097/DSS.0000000000001755
Original Article

BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.

OBJECTIVE To evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.

MATERIALS AND METHODS Medical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.

RESULTS Of the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1–46.8 months).

CONCLUSION As most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.

Departments of *Dermatology,

Radiation Oncology, and

Medical Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, California;

§University of Colorado Cancer Center, University of Colorado, Aurora, Colorado

Address correspondence and reprint requests to: Shauna Higgins, MD, 830 S. Flower Street, Suite 100, Los Angeles, CA 90017, or e-mail:

The authors have indicated no significant interest with commercial supporters.

© 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website